Clinical and Experimental Nephrology

, Volume 16, Issue 3, pp 485–489 | Cite as

Accelerated recovery from nephrotic syndrome with acute renal failure by double filtration plasmapheresis in a patient with lupus podocytopathy

  • Yoshitaka Iwazu
  • Tetsu Akimoto
  • Sayoko Izawa
  • Makoto Inoue
  • Shigeaki Muto
  • Yasuhiro Ando
  • Kana Iwazu
  • Noriyoshi Fukushima
  • Wako Yumura
  • Eiji Kusano
Case Report


We describe a case of an adult female who presented with nephrotic syndrome. She was diagnosed with systemic lupus erythematosus with serum antinuclear antibodies, leucopenia with lymphopenia, butterfly erythema, and nephrotic syndrome. Renal biopsy revealed normal glomeruli with diffuse effacement of the foot processes, consistent with lupus podocytopathy. Although human albumin replacement was performed initially, acute renal failure developed rapidly. Therefore, she was treated with double filtration plasmapheresis (DFPP) in addition to oral steroid. After steroid therapy combined with DFPP, the renal function and proteinuria improved rapidly. Although the impact of DFPP on the treatment of lupus nephritis remains to be delineated, our observations suggest that DFPP in lupus podocytopathy played a pivotal role in facilitating the early recovery from renal injuries. Because of the rapid improvement of renal function without any change in body weight by DFPP, acute renal failure in the setting of lupus podocytopathy might contribute to an alternative pathophysiological factor for the diminished glomerular filtration rate, similar to that observed in the setting of idiopathic minimal change glomerulopathy.


Systemic lupus erythematosus Lupus podocytopathy Double filtration plasmapheresis Acute renal failure 


  1. 1.
    Dube GK, Markowitz GS, Randhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57:120–6.PubMedGoogle Scholar
  2. 2.
    Hertig A, Droz D, Lesavre P, Grunfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis. 2002;40:1179–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16:175–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Masuda T, Akimoto T, Ando Y, Kobayashi T, Meguro D, Muto S, et al. Changes in the urinary excretion of beta2-microglobulin (beta 2MG) and N-acetyl-beta-d-glucosaminidase (NAG) during treatment for lupus nephritis. Intern Med. 2008;47:287–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher. 2002;17:72–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Huang DF, Tsai ST, Wang SR. Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfus Sci. 1994;15:283–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Sulowicz W, Stompór T. LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. Nephrol Dial Transplant. 2003;18(Suppl 5):v59–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Braun N, Erley C, Klein R, Kötter I, Saal J, Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant. 2000;15:1367–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum. 2001;44:1962–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jiménez-Boj E, Hörl WH, et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis. 2005;64:1015–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Nakamura T, Ushiyama C, Hara M, Osada S, Ugai K, Shimada N, et al. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative lupus nephritis. Clin Nephrol. 2002;57:108–13.PubMedGoogle Scholar
  12. 12.
    Endo S, Inada K, Nakae H, Takakuwa T, Kasai T, Yamada Y, et al. Blood levels of endothelin-1 and thrombomodulin in patients with disseminated intravascular coagulation and sepsis. Res Commun Mol Pathol Pharmacol. 1995;90:277–88.PubMedGoogle Scholar
  13. 13.
    Boehme MW, Nawroth PP, Kling E, Lin J, Amiral J, Riedesel J, et al. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1994;37:572–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Boehme MWJ, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin—a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol. 2000;119:189–95.PubMedCrossRefGoogle Scholar
  15. 15.
    Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheumatol. 2001;28:514–9.PubMedGoogle Scholar
  16. 16.
    Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology. 2003;42:117–22.PubMedCrossRefGoogle Scholar
  17. 17.
    Shea-Simonds P, Cairns TD, Roufosse C, Cook T, Vyse TJ. Lupus podocytopathy. Rheumatology. 2009;48:1616–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Horino T, Takao T, Morita T, Ito H, Hashimoto K. Minimal change nephrotic syndrome associated with systemic lupus erythematosus. Nephrol Dial Transplant. 2006;21:230.PubMedCrossRefGoogle Scholar
  19. 19.
    Deji N, Sugimoto T, Kanasaki M, Aoyama M, Tanaka Y, Sakaguchi M, et al. Emerging minimal-change nephrotic syndrome in a patient with chronic mesangial proliferative lupus nephritis. Intern Med. 2007;46:991–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Seo DB, Lee SW, Song JH, Lee KJ, Han JY, Kim MJ. Acute renal failure associated with a minimal change nephrotic syndrome in a systemic lupus erythematosus patient. Yonsei Med J. 2002;43:114–8.PubMedGoogle Scholar
  21. 21.
    Cameron MA, Peri U, Rogers TE, Moe OW. Minimal change disease with acute renal failure: a case against the nephrosarca hypothesis. Nephrol Dial Transplant. 2004;19:2642–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Libit SA, Burke BA, Michael AF, Vernier RL. Extramembranous glomerulonephritis in childhood: relationship to systemic lupus erythematosus. J Pediatr. 1976;88:394–402.PubMedCrossRefGoogle Scholar
  23. 23.
    Shearn MA, Hopper J, Biava CG. Membranous lupus nephropathy initially seen as idiopathic membranous nephropathy. Possible diagnostic value of tubular reticular structures. Arch Intern Med. 1980;140:1521–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Feldman D, Goldstein AL, Cox DC, Grimley PM. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2′,5′ oligoadenylate synthetase induction. Lab Invest. 1988;58:584–9.PubMedGoogle Scholar
  25. 25.
    Venkataseshan VS, Marquet E, Grishman E. Significance of cytoplasmic inclusions in lupus nephritis. Ultrastruct Pathol. 1991;15:1–14.PubMedCrossRefGoogle Scholar
  26. 26.
    Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int. 1983;24:377–85.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2012

Authors and Affiliations

  • Yoshitaka Iwazu
    • 1
  • Tetsu Akimoto
    • 1
  • Sayoko Izawa
    • 1
  • Makoto Inoue
    • 1
  • Shigeaki Muto
    • 1
  • Yasuhiro Ando
    • 1
  • Kana Iwazu
    • 1
  • Noriyoshi Fukushima
    • 2
  • Wako Yumura
    • 1
  • Eiji Kusano
    • 1
  1. 1.Division of Nephrology, Department of Internal MedicineJichi Medical UniversityShimotsukeJapan
  2. 2.Department of Diagnostic PathologyJichi Medical UniversityShimotsukeJapan

Personalised recommendations